Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.
One selected publication reports two randomized phase 1 trials of petrelintide. This overview concerns early pharmacology, tolerability and weight observations, without a direct comparison with other weight-management medicines.↗
What the reviewed sources report
The trials reported weight reductions and predominantly mild gastrointestinal adverse events. The early-phase design and limited follow-up do not establish long-term benefit or superior tolerability to another medicine.↗
What remains unresolved?
What do larger, longer controlled trials establish about sustained weight changes and uncommon adverse events?↗
Do head-to-head trials support any comparative benefit or tolerability claim?↗
NCT06662539 records 493 participants in a placebo-controlled phase 2 study of overweight or obesity. The eligibility criteria exclude diabetes and diabetic-range HbA1c, defining a different population from the diabetes program. NCT06662539 ↗
More findings and the sources behind them
Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal.
ZUPREME 2 includes specified background diabetes treatment
NCT06926842 records 221 participants with type 2 diabetes treated with stable metformin, with or without an SGLT2 inhibitor. That background matters when interpreting glycemic or safety findings eventually reported. NCT06926842 ↗
Both primary endpoints concern weight at 28 weeks
Both records specify percentage body-weight change through week 28. This endpoint does not directly measure cardiovascular events, sustained benefit after stopping treatment, or every obesity-related complication. NCT06662539 ↗NCT06926842 ↗
The status updates are not efficacy results
Both retrieved records are marked completed, but neither includes posted summary results. ZUPREME 2 was last updated on September 9, 2026. Any effect estimate needs a separate results source rather than being inferred from completion. NCT06662539 ↗NCT06926842 ↗
What remains to be checked
Match ZUPREME publications or subsequent registry results to each protocol before adding effect estimates.
Review durability, discontinuation, gastrointestinal events and other safety findings in the diabetes and non-diabetes populations separately.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Primary reports of the named peptide administered in people, including pharmacology and secondary human-sample analyses. Reviews, modeling and preclinical reports remain indexed but are outside this human-administration subset.
7 retrieved · 1 included · 6 excluded · 0 awaiting a decision · 1 full-text appraisals
Search terms, record decisions and remaining work
"petrelintide"[Title/Abstract] OR "ZP8396"[Title/Abstract]
Eligibility decisions use titles and abstracts from the pinned PubMed results; unavailable details remain unresolved rather than inferred.
Full-text appraisal, study-family reconciliation, registry history and broader alias/jurisdiction searches remain separate open work.
Showing 7 of 7 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 42017294 — include: Two original randomized phase 1 human studies reported in one paper; full-text reading and study-family comparison are separate review steps. Study families: EudraCT-2021-001712-28; EudraCT-2022-001744-26.Structured full-text reading · PMC13243934
This is an editorial structured reading, not a validated risk-of-bias score.
Methods describe an independent unblinded randomization programmer, masked identical vials, and blinded participants and trial staff. Two trials and their cohorts are reported in one paper.
Missing data
Results report 133 randomized and 132 treated. All participants completed the single-exposure trial and the first multiple-exposure part; three active-group participants discontinued in the later part. Weight estimates include a post hoc repeated-measures model.
Outcome selection
Safety and tolerability were primary; body-weight changes were secondary. No formal sample-size calculation was performed. Registry protocols and supplementary tables have not yet been independently reconciled, so selective-reporting risk remains unresolved.
Applicability
One German research center enrolled otherwise healthy adults with normal weight, overweight or obesity. The later part included 48 people, all White and mostly men; observation lasted 16 weeks. No active comparator supports claims of superior tolerability.
Funding and conflicts
Zealand Pharma sponsored the trials and manuscript and participated in design, collection and publication. Several authors were employees or shareholders. This is a potential influence to consider, not evidence that results are false.
Registry comparison
The paper identifies EudraCT 2021-001712-28 and 2022-001744-26. Independent comparison of registered outcomes, amendments and supplements is still pending.
PubMed 42586227 — exclude: Review of the amylin evidence base, not a new administered human study.
PubMed 42452898 — exclude: Review of the amylin evidence base, not a new administered human study.
PubMed 41747885 — exclude: Review of the amylin evidence base, not a new administered human study.
PubMed 41344603 — exclude: Review of the amylin evidence base, not a new administered human study.
PubMed 41217931 — exclude: Compound-development and preclinical potency report; the abstract describes clinical development rather than reporting a human administration trial.
PubMed 40608546 — exclude: Preclinical development of a different analogue, BGM1812, not a human petrelintide administration report.
ClinicalTrials.gov search
ClinicalTrials.gov API v2 identity-name search, complete retrieved records. Includes protocols, extensions, combinations and expanded access; these are not all efficacy trials or published outcomes.
9 retrieved · 8 included · 0 excluded · 1 awaiting a decision · 0 full-text appraisals
Registry identity screening is distinct from appraisal of posted results, protocol history and publication linkage.
Other registries and unregistered studies are outside this search.
Petrelintide has one ambiguous registry identity; the second trial publication linkage remains incompletely reconciled.
Showing 9 of 9 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT07338214 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07338214.
ClinicalTrials.gov NCT05096598 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT05096598.
ClinicalTrials.gov NCT06926842 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06926842.
ClinicalTrials.gov NCT06662539 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT06662539.
ClinicalTrials.gov NCT07076030 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07076030.
ClinicalTrials.gov NCT05613387 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT05613387.
ClinicalTrials.gov NCT07589686 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07589686.
ClinicalTrials.gov NCT07682818 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07682818.
ClinicalTrials.gov NCT06951854 — unresolved: Autism NV01-A02 record contains a conflicting placebo name mentioning ZP8396; identity is unresolved.
FDA search
Exact active-ingredient terms in the openFDA Drugs@FDA endpoint, checked September 15. A zero result describes this indexed query only, not worldwide nonapproval or every FDA document.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
products.active_ingredients.name:"PETRELINTIDE" OR products.active_ingredients.name:"ZP8396"
This query does not cover all FDA safety communications, labels, compounding proceedings or other regulatory systems.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local identity matching in the pinned EMA medicines metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
Case-insensitive word-boundary matching of reviewed identity terms: ["petrelintide", "ZP8396", "ZP-8396"]
Complete source-document appraisal and national European sources remain open.
Zero identity matches apply only to these feed fields and terms.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local identity matching in the pinned EMA documents metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
Case-insensitive word-boundary matching of reviewed identity terms: ["petrelintide", "ZP8396", "ZP-8396"]
Complete source-document appraisal and national European sources remain open.
Zero identity matches apply only to these feed fields and terms.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local identity matching in the pinned EMA orphans metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
Case-insensitive word-boundary matching of reviewed identity terms: ["petrelintide", "ZP8396", "ZP-8396"]
Complete source-document appraisal and national European sources remain open.
Zero identity matches apply only to these feed fields and terms.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Read the full Human Evidence Review
Supervised synthesis
What do selected human studies report about Petrelintide?
One selected publication reports two randomized phase 1 trials of petrelintide. This overview concerns early pharmacology, tolerability and weight observations, without a direct comparison with other weight-management medicines.1
Bottom line from this bounded source set
The trials reported weight reductions and predominantly mild gastrointestinal adverse events. The early-phase design and limited follow-up do not establish long-term benefit or superior tolerability to another medicine.1
Reviewed study record
Two early randomized trials
Design
Single- and multiple-ascending-exposure trials were randomized, blinded and placebo controlled; one part followed participants for 16 weeks.1
Population
Earlier parts enrolled normal-weight or overweight adults; the later multiple-exposure part enrolled adults with overweight or obesity. The abstract does not give total enrollment.1
Outcomes reported
The report described weight reductions and no serious or severe treatment-emergent adverse events. One participant discontinued because of gastrointestinal events.1
Limitations
The trials primarily assess early safety and pharmacology. Their size, follow-up and lack of an active comparator do not establish comparative tolerability or exclude uncommon harms.1
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1111/dom.70753. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Petrelintide?
Investigational. ClinicalTrials.gov lists a Roche-sponsored combination study as not yet recruiting, updated July 7, 2026.↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Status at observationCompleted 3Not yet recruiting 1Recruiting 1
A phase value is unavailable here for 2 selected records; this is not counted as “no phase.”
A status value is unavailable here for 2 selected records; this is not counted as a trial status.
PubMed bibliography
Publication composition
0 of 1 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Bibliography fields unavailable here for 1 selected record; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
8
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
PeptideScanner retained ClinicalTrials.gov record NCT06926842 at 2026-09-09T19:17:17.080Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was petrelintide.
PeptideScanner retained ClinicalTrials.gov record NCT07076030 at 2026-07-30T16:25:18.009Z. Its registry update date was 2026-01-28, and PeptideScanner's reviewed identity mapping was petrelintide.
PeptideScanner retained ClinicalTrials.gov record NCT06662539 at 2026-07-30T16:22:22.334Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was petrelintide.
Counts and links describe PeptideScanner’s selected records. They are not rankings and do not establish research quality, safety, effectiveness, or medical relevance.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
These dates come from selected source records and PubMed metadata. They are not a complete or continuous timeline of research, safety, approval, or effectiveness.
Evidence summary
What the cited records say
ClinicalTrials.gov lists a Roche-sponsored combination study as not yet recruiting, updated July 7, 2026.↗
This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.
PeptideScanner retained ClinicalTrials.gov record NCT06926842 at 2026-09-09T19:17:17.080Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was petrelintide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07589686 at 2026-08-13T05:52:27.014Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was petrelintide.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42017294 at 2026-08-10T18:13:48.775Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-04-22. PeptideScanner associated this retained record with the identity slug petrelintide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained ClinicalTrials.gov record NCT07682818 at 2026-08-10T18:10:03.938Z. Its registry update date was 2026-07-06, and PeptideScanner's reviewed identity mapping was petrelintide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07338214 at 2026-07-30T16:20:49.304Z. Its registry update date was 2026-04-08, and PeptideScanner's reviewed identity mapping was petrelintide.↗
PeptideScanner retained ClinicalTrials.gov record NCT06662539 at 2026-07-30T16:22:22.334Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was petrelintide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07076030 at 2026-07-30T16:25:18.009Z. Its registry update date was 2026-01-28, and PeptideScanner's reviewed identity mapping was petrelintide.↗